Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 5/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131590 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAMAPK1ALDH1A1THRB | |
| SCHEMBL11777752 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAMAPK1ALDH1A1THRB | |
| SCHEMBL24270457 | 0.76 | LMNA (0.58) | SMN1; SMN2LMNAMAPK1ALDH1A1THRB | |
| SCHEMBL12391228 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAMAPK1ALDH1A1THRB | |
| SCHEMBL15177274 | 0.72 | LMNA (0.46) | SMN1; SMN2LMNAMAPK1ALDH1A1THRB | |
| Bromide SCHEMBL17079938 | 0.72 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAMAPK1ALDH1A1THRB | |
| SCHEMBL6131601 | 0.71 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAALDH1A1THRBMITF | |
| SCHEMBL18633377 | 0.71 | CHRM1 (0.63) | SMN1; SMN2LMNAMAPK1ALDH1A1THRB | |
| SCHEMBL17198863 | 0.68 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAMAPK1ALDH1A1THRB | |
| SCHEMBL4962139 | 0.68 | ENO1 (0.40) | SMN1; SMN2LMNAMAPK1ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | BRACCO SUISSE SA (CH) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | HIF1A, HIF1AN, SLC2A8 | SMN1; SMN2 3718/4885LMNA 4114/4885MAPK1 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.